Table 4 Multivariate analysis of the clinical factors for PFS or OS in patients with mPDAC who received nal-IRI plus 5-FU/LV

Age (≥65 vs. < 65 years)

0.80 (0.40–1.64)

0.554

1.09 (0.51–2.35)

0.824

Prior lines of chemotherapy (2 vs. 1)

1.82 (0.83–3.98)

0.132

1.78 (0.72–4.38)

0.213

Liver metastases

1.02 (0.40–2.58)

0.967

1.10 (0.49–2.52)

0.803

Peritoneum metastases

0.79 (0.36–1.72)

0.553

0.94 (0.42–2.08)

0.936

Bone metastases

1.54 (0.58–4.10)

0.386

3.06 (1.06–8.82)

0.038

Metastatic burden (> 3 vs. 1–3)

2.17 (1.01–4.64)

0.046

1.71 (0.74–3.93)

0.210

RDI (< 85% vs. ≥85%)

0.47 (0.23–0.99)

0.047

0.62 (0.30–1.28)

0.195

NLR (> 5 vs. ≤5)

0.82 (0.36–1.87)

0.635

1.47 (0.64–3.37)

0.364